PRV-101 is under clinical development by Provention Bio and currently in Phase I for Enterovirus Infections. According to GlobalData, Phase I drugs for Enterovirus Infections have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PRV-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRV-101 is under development for the prevention of Coxsackie virus B infection, type 1 diabetes and celiac disease. The candidate is a polyvalent enterovirus vaccine. It is comprised of coxsackie B virus. It is administered through intramuscular route.
Provention Bio overview
Provention Bio (Provention), is a clinical-stage biopharmaceutical company. It develops novel therapeutics for intercepting and preventing immune-mediated diseases. The company’s pipeline product portfolio includes PRV-031 teplizumab for the treatment of type one diabetes (T1D); PRV-015 is an anti-IL-15 monoclonal antibody for gluten-free diet non-responsive celiac disease (NRCD). It also develops PRV-3279 for preventing immunogenicity and SLE; PRV-101 is a polyvalent coxsackievirus B (CVB) vaccine developed for treating type one diabetes (T1D). Provention has licensing and co-development agreement with pharmaceutical and biotherapeutic industries includes Vactech Oy, Amgen Inc and MacroGenics Inc. Provention is headqutered in Red Bank, New Jersey, the US.
For a complete picture of PRV-101’s drug-specific PTSR and LoA scores, buy the report here.